Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
US Dept. of Health & Human Services: National Institutes of Health (NIH)Suggest an update
Deadline: Jan 23, 2021
Grant amount: Up to US $9,000,000
Fields of work: Respiratory Diseases & Systems Infectious & Parasitic Diseases
Applicant type: Organizations
Funding uses: Clinical Biomedical
Location of project: United States
Location of residency: United StatesView website Save
NOTE: Applications will be accepted on a rolling basis, beginning on August 6, 2020. All applications are due by 5:00 PM local time of applicant organization.
The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.
We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.